Allogene Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Allogene Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Allogene Therapeutics Inc
Rating: 1.12241675
Author: Trendlyne DVM scores

about

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...

1.69 0.00 (0.00%)

62.11% Fall from 52W High

6.0M

XNAS Volume

XNAS 21 Sep, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

14.2 / 100

Technically Bearish

30.7 / 100

1Yr Price target upside is 342%

12 analysts

Allogene Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Allogene Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...

62.11% Fall from 52W High

SWOT Analysis

Allogene Therapeutics Inc Live Price Chart

Allogene Therapeutics Inc Live Price Chart